Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099918 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 717
- Enrollment target
NCT00099918: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00099918 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 717 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099918, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 717 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
Interventions
- DRUG vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00099918 record still lists
NCT00099918 is an interventional study that assigns participants to a tested intervention. The registered 717 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which vildagliptin is the first listed.
NCT00099918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00099918 about?
NCT00099918 is a clinical study titled "Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes". The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
What is the current status of trial NCT00099918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 717 participants. The study started on 2004-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00099918?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00099918?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00099918's enrollment target sits among peer trials
717 498th of 2000 higher than 1,503 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia